ALBALON Drug Patent Profile
✉ Email this page to a colleague
When do Albalon patents expire, and when can generic versions of Albalon launch?
Albalon is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in ALBALON is naphazoline hydrochloride. There are eight drug master file entries for this compound. Additional details are available on the naphazoline hydrochloride profile page.
Summary for ALBALON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 91 |
Patent Applications: | 2,152 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ALBALON at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ALBALON
US Patents and Regulatory Information for ALBALON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | ALBALON | naphazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 080248-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |